Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brigatinib · Alunbrig, AP-26113

Small molecule · Inhibitor of anaplastic lymphoma kinase (ALK) · developed by Takeda Pharms Usa

Approved FDA, Apr 2017
TAK Developer
1 Registered trials

What is Brigatinib?

Brigatinib is a tyrosine kinase inhibitor that blocks ALK autophosphorylation and downstream signaling, and also acts on ROS1, IGF-1R, FLT3 and EGFR mutants in vitro.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Alunbrig, AP-26113
Drug type
Small molecule
Targets
anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1) (secondary target), insulin-like growth factor 1 receptor (IGF1R) (secondary target), FMS-like tyrosine kinase 3 (FLT3) (secondary target), epidermal growth factor receptor (EGFR) (secondary target)
Mechanism
Inhibitor of anaplastic lymphoma kinase (ALK)
Pathways
STAT3 signaling, PI3K/AKT signaling, MAPK/ERK signaling, S6 phosphorylation
Therapy area
Oncology
Developer
Takeda Pharms Usa (TAK)
FDA status
Approved as Alunbrig (April 28, 2017), NDA208772 · FDA label
UNII
HYW8DB273J

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 12, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04374305 Phase 2 Neurofibromatosis Type 2 Recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

EpendymomaMeningiomaNeurofibromatosis Type 2Non-vestibular SchwannomaVestibular Schwannoma

Other drugs acting on ALK

More from Takeda Pharms Usa

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Brigatinib

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.